Quantitative Single-Photon Emission Computed Tomography/Computed Tomography for Evaluation of Salivary Gland Dysfunction in Sjögren’s Syndrome Patients

被引：17

作者：

Kim J. ^{[1
]}

Lee H. ^{[1
]}

Bang J.-I. ^{[2
]}

Kang Y.-K. ^{[1
]}

Bae S. ^{[1
]}

Song Y.S. ^{[1
]}

Lee W.W. ^{[1
,3
]}

机构：

[1] Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, 13620, Gyeonggi-do

[2] Department of Nuclear Medicine, Ewha Womans University School of Medicine, Seoul

[3] Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul

来源：

Nuclear Medicine and Molecular Imaging | 2018年 / 52卷 / 5期

基金：

新加坡国家研究基金会;

关键词：

Computed tomography; Quantitation; Single-photon emission computed tomography; Sjögren’s syndrome; Tc-99m pertechnetate;

D O I：

10.1007/s13139-018-0547-4

中图分类号：

学科分类号：

摘要：

Purpose: The purpose of the study was to investigate the usefulness of quantitative salivary single-photon emission computed tomography/computed tomography (SPECT/CT) using Tc-99m pertechnetate in Sjögren’s syndrome (SS). Methods: We retrospectively reviewed quantitative salivary SPECT/CT data from 95 xerostomic patients who were classified as either SS (n = 47, male:female = 0:47, age = 54.60 ± 13.16 y [mean ± SD]) or non-SS (n = 48, male:female = 5:43, age = 54.94 ± 14.04 y) by combination of anti-SSA/Ro antibody, labial salivary gland biopsy, unstimulated whole saliva flow rate, and Schirmer’s test. Thyroid cancer patients (n = 43, male:female = 19:24, age = 46.37 ± 12.13 y) before radioactive iodine therapy served as negative controls. Quantitative SPECT/CT was performed pre-stimulatory 20 min and post-stimulatory 40 min after injection of Tc-99m pertechnetate (15 mCi). The %injected dose at 20 min and the %excretion between 20 and 40 min were calculated for parotid and submandibular glands, generating four quantitative parameters: %parotid uptake (%PU), %submandibular uptake (%SU), %parotid excretion (%PE), and %submandibular excretion (%SE). The most useful parameter for SS diagnosis was investigated. Results: The uptake parameters (%PU and %SU) were significantly different among the SS, non-SS, and negative controls (p = 0.005 for %PU and p < 0.001 for %SU, respectively), but the excretion parameters (%PE and %SE) were not (p > 0.05 for both). The %PU and %SU were significantly lower in SS than in the negative controls and non-SS (p < 0.05 for all pair-wise comparisons). Additionally, the %SU was significantly lower in non-SS than in the negative controls (p < 0.05). Receiver-operating characteristic analysis revealed that the %SU had the greatest area-under-the curve of 0.720 (95% confidence interval = 0.618–0.807). Using the optimal cut-off value of %SU ≤ 0.07%, SS was identified with a sensitivity of 70.21% and a specificity of 70.83%. Conclusion: Reduced submandibular uptake of Tc-99m pertechnetate at 20 min (%SU) was proved useful for the diagnosis of SS. Quantitative salivary gland SPECT/CT holds promise as an objective imaging modality for assessment of salivary dysfunction and may facilitate accurate classification of SS. © 2018, Korean Society of Nuclear Medicine.

引用

页码：368 / 376

页数：8

共 42 条

[1]

Manthorpe R., Frost-Larsen K., Isager H., Prause J.U., Sjogren's syndrome. A review with emphasis on immunological features, Allergy, 36, pp. 139-153, (1981)

[2]

Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., Et al., Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group, Ann Rheum Dis, 61, pp. 554-558, (2002)

[3]

Shiboski C.H., Shiboski S.C., Seror R., Criswell L.A., Labetoulle M., Lietman T.M., Et al., 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts, Ann Rheum Dis, 76, pp. 9-16, (2017)

[4]

Vitali C., Bombardieri S., Moutsopoulos H.M., Balestrieri G., Bencivelli W., Bernstein R.M., Et al., Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European Community, Arthritis Rheum, 36, pp. 340-347, (1993)

[5]

Fujibayashi T., Sugai S., Miyasaka N., Hayashi Y., Tsubota K., Revised Japanese criteria for Sjogren's syndrome (1999): availability and validity, Mod Rheumatol, 14, pp. 425-434, (2004)

[6]

Fox R.I., Robinson C.A., Curd J.G., Kozin F., Howell F.V., Sjogren's syndrome. Proposed criteria for classification, Arthritis Rheum, 29, pp. 577-585, (1986)

[7]

Shiboski S.C., Shiboski C.H., Criswell L., Baer A., Challacombe S., Lanfranchi H., Et al., American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort, Arthritis Care Res, 64, pp. 475-487, (2012)

[8]

Vivino F.B., Hermann G.A., Role of nuclear scintigraphy in the characterization and management of the salivary component of Sjogren's syndrome, Rheum Dis Clin N Am, 34, pp. 973-986, (2008)

[9]

Schall G.L., Anderson L.G., Wolf R.O., Herdt J.R., Tarpley T.M., Cummings N.A., Et al., Xerostomia in Sjogren's syndrome. Evaluation by sequential salivary scintigraphy, JAMA, 216, pp. 2109-2116, (1971)

[10]

Schall G.L., Larson S.M., Anderson L.G., Griffith J.M., Quantification of parotid gland uptake of pertechnetate using a gamma scintillation camera and a “region-of-interest” system, Am J Roentgenol Radium Therapy, Nucl Med, 115, pp. 689-697, (1972)

← 1 2 3 4 5 →